Open Access

Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors

Molecular Pain20139:45

https://doi.org/10.1186/1744-8069-9-45

Received: 4 June 2013

Accepted: 3 September 2013

Published: 8 September 2013

Abstract

Opioids are widely used as the pain reliever and also notorious for being addictive drugs. Sex differences in the opioid analgesia and addiction have been reported and investigated in human subjects and animal models. Yet, the molecular mechanism underlying the differences between males and females is still unclear. Here, we reviewed the literature describing the sex differences in analgesic responses and addiction liabilities to clinically relevant opioids. The reported interactions among opioids, estrogens, opioid receptors, and estrogen receptors are also evaluated. We postulate that the sex differences partly originated from the crosstalk among the estrogen and opioid receptors when stimulated by the exogenous opioids, possibly through common secondary messengers and the downstream gene transcriptional regulators.

Keywords

Sex differences Opioid analgesia Opioid addiction Opioid receptors Estrogen receptors

Review

Introduction

Opioids are potent analgesics used to treat acute and chronic pain, and also notorious for their potential to cause addiction [14]. Gender differences in the experience of clinical and experimental pain [57] and the susceptibility to opioid addiction [8] have been reported. General observations suggest that there are more adult men than women involved in illicit drug abuse [9]. However, this contrasts to the clinical and animal studies indicating that females are more susceptible to drug abuse problem than males [10]. Besides the sociocultural factors, there must be true differences between the biological differences that influence drug abuse and pain perception, and estrogen has been proposed to be one of the key players [11, 12].

Sex differences in opioid analgesia and addiction

Population-based studies suggest that women are more likely to experience chronic pain syndromes and report more severe pain at a higher frequency than men [1319]. Human studies indicate that females and males have similar thresholds for cold and ischemic pain [20, 21], while pressure pain thresholds are lower in females than males [22, 23]. Females tolerate less thermal pain (cold, heat) and pressure than males [2426], but this is not the case for tolerance to ischemic pain, which is comparable in both genders [27, 28]. Based on a review of the available literature published between 1966 and 1998, Miaskowski and Levine suggest that opioids are better analgesics for women [29]. A Chinese population study conducted in southern Taiwan also shows that females consume significantly less morphine via patient-controlled analgesia than males during the first three postoperative days [30]. However, the majority of more recent studies comparing gender report that the potency and efficacy of morphine administered systemically is higher in males than in females against a variety of nociceptive modalities [3133]. The controversy might be due to that earlier studies did not correct for the body weight differences between men and women. In addition, there are sex differences in reporting pain and seeking pain relief, and health care providers make unwarranted psychogenic attributions regarding pain in female but not male [7, 3436].

A profile of a heroin-addiction epidemic showed that 74 percent of the addicts are males [37]. In the United States, the past year and life time rates of heroin use are higher among men (men = 0.2% vs. women = 0.1%; 2.3% vs. 0.8%, respectively), while equivalent rates of men and women are reported to inject heroin (42.0% vs. 40.7%) [8]. Among adolescent drug users administrated during 2002–2003 in the National Survey on Drug Use and Health, females are 3.91 times more likely to inject heroin than males [38]. Gender differences in the clinical profiles of opioid-dependent individuals have been observed in substance use severity, craving, medical conditions, and impairment in associated areas of functioning. Craving for opioids is significantly higher among women, and women have higher drug, employment, family, medical, and psychiatric Addiction Severity Index composite scores [8]. Among patients entering the maintenance program in Italy, there seems to be an emerging pattern of males who tend to use heroin as their opiate of choice, and are more likely to combine it with cannabis, while females are more likely to using street methadone, with adjunctive use of ketamine, benzodiazepines, hypnotic drugs and/or amphetamines [39]. Moreover, women are at higher risk of abusing opioids through initial prescription painkiller use, and later resort to street methadone to cope with prescription pain killer addiction [39]. Analysis from the U.S. indicates that opioid-addicted women work less and use more cocaine than their male counterparts [40]. The use of drugs of abuse in women may be influenced by psychosocial and hormonal factors, such as psychiatric comorbidity (a higher rate of anxiety disorders) [4144], more distressing drug-related environment, lower rate of antisocial personality traits [45], and estrogen-regulated neuroendocrine functions [12, 39, 46]. Sex differences in opioid analgesia and addiction in human and animals have been investigated extensively, and clinically-relevant representative studies are listed in Tables 1 and 2. Effects of opioids are inconsistent among different studies and species, which might result from different genetic backgrounds, ages of the subjects, doses of the opioids used, and assays or end points of the measurements.
Table 1

Sex differences in opioid analgesia and addiction in human

Opioid

Receptor

Model

Effect

Reference

Buprenorphine

ORL1 agonist

Postoperative pain

M < F

[4749]

MOR partial agonist

KOR antagonist

Butorphanol

MOR partial agonist

Acute injury

M = F

[50]

KOR agonist

Thermal, pressure, and ischemic pain (experimental)

M = F

[51]

Postoperative dental surgery

M < F

[52]

Cold-water stimulus (experimental)

M > F

[53]

Fentanyl

MOR agonist

Postoperative pain

M < F

[54]

 

M = F

[55]

Ketobemidone

MOR agonist

Postoperative pain

M = F

[56]

NMDA antagonist

Methadone

MOR agonist

Cancer pain

M = F

[57]

Morphine

MOR agonist

Acute injury

M > F

[50]

KOR agonist

Thermal, pressure, and ischemic pain (experimental)

M = F

[51]

DOR agonist

   

Postoperative pain

M > F

[32, 33]

M = F

[5860]

M < F

[30, 6164]

Nalbuphine

KOR agonist

Postoperative pain

M = F

[65]

MOR antagonist

Postoperative dental surgery

M < F

[52, 66]

Pentazocine

KOR agonist

Acute pain (experimental)

M = F

[67, 68]

MOR partial agonist

 

M < F

[69]

Postoperative dental surgery

M < F

[70]

Pethidine

MOR agonist

Postoperative pain

M = F

[60, 71]

KOR agonist

Heroin

MOR agonist

Addiction epidemic

M > F

[8, 37]

KOR agonist

Adolescent drug users

M < F

[38]

DOR agonist

   
Table 2

Sex differences in opioid analgesia and addiction in animals

Opioid

Receptor

Species

Model

Effect

Reference

Buprenorphine

ORL1 agonist

Rat

Hot plate

M = F

[72]

MOR partial agonist

Tail withdrawal

M > F

[7375]

KOR antagonist

   

M = F

[72]

Temporal summation (thermal stimulus / tail withdrawal)

M > F

[76]

Butorphanol

MOR partial agonist

Rat

Capsaicin-induced hyperalgesia (Tail withdrawal)

M = F

[77]

KOR agonist

Temporal summation (thermal stimulus / tail withdrawal)

M > F

[76]

Fentanyl

MOR agonist

Rat

Tail flick

M = F

[78]

Methadone

MOR agonist

Rat

Tail flick

M > F

[79]

Morphine

MOR agonist

Rat

Abdominal constriction

M > F

[80, 81]

KOR agonist

Hot plate

M > F

[81]–[86]

DOR agonist

 

M < F

[87]

Tail flick

M > F

[76, 81, 8894]

M = F

[95]

Tail withdrawal

M > F

[74, 75, 85, 86]

Temporal summation (thermal stimulus / tail withdrawal)

M > F

[96]

Mouse

Hot plate

M > F

[9799]

Tail Flick

M > F

[100]

Tail Withdrawal

M > F

[101, 102]

M = F

[101]

M < F

[101]

Nalbuphine

KOR agonist

Rat

Tail withdrawal

M > F

[74, 103, 104]

MOR antagonist

Heroin

MOR agonist

Rat

Acquisition of self-administration

M < F

[105107]

KOR agonist

DOR agonist

Factors contributing to sex differences in drug abuse include pharmacokinetics, behavioral phenotypes for drug abuse vulnerability, sensitivity to aversive properties of drugs, puberty and adolescence, and genetic factors beyond hormones as reviewed by Wetherington [108]. Given the ubiquitous actions and gender differences of sex hormones in the central nervous system, many investigators have attempted to relate sex differences in opioid analgesia to gonadal hormone levels [73, 8082, 8893, 100, 109118]. Yet, the neurological and cellular mechanisms underlying the sexually dimorphic analgesic and addictive responsiveness to opioids remain poorly understood [31].

Estrogen regulation of opioid receptors

The analgesic effects and addiction liability of opioids are mediated by opioid receptors. Based on the molecular and pharmacological properties, three conventional opioid receptors – μ (MOR), δ (DOR), and κ (KOR) – have been characterized [119]. A non-opioid branch of opioid receptors, opioid receptor-like 1 (ORL1) receptor, also known as the nociceptin/orphanin FQ peptide (NOP) receptor, has also been identified and displays pharmacological profiles distinct from those of conventional opioid receptors [120]. Activation of opioid receptors inhibits (acute) / superactivates (chronic) adenylate cyclase (AC) activity [121], impedes N- and L-type Ca2+ channels, increases phospholipase C activity, activates inwardly rectifying K+ channels, and turns on mitogen-activated protein kinases (MAPK) [122, 123].

Estrogens, besides the well-established effects on female reproductive functions, exert various actions on the nervous system influencing pain sensation, mood, susceptibility to seizures, and neuroprotection against stroke damage and Alzheimer’s disease [124]. Ovarian steroids have been found to modulate the activity of opioid receptors in healthy women and migraine sufferers [125], and replacement therapies through estrogens and progestagens could restore the activity of central opioid tonus in migraine patients [125]. Estrogen has also been demonstrated to decrease the secretion of β-endorphin, an endogenous opioid peptide, from the Ishikawa cells, an endometrial carcinoma cell line, in a concentration- and time-dependent manner [126]. The spinal KOR and DOR, but not MOR, activity is required for opioid-mediated elevations in maternal nociceptive thresholds, indicating the ability of estrogen to modulate spinal opioid antinociceptive activity [127].

Sexually dimorphic KOR-mediated antinociception has been demonstrated in antithetical antinociceptive/nociceptive responsiveness of female vs. males to KOR agonists-antagonists [128]. Compared to men, women reported greater analgesic effects from the mixed MOR/KOR ligands: pentazocine, nalbuphine and butorphanol [52, 66]. In contrast, selective KOR agonists produced greater antinociceptive effects in male than female animals [129]. An animal study demonstrated that spinal morphine antinociception in females requires concomitant activation of MOR and KOR, and the expression of MOR/KOR heterodimers is more prominent in the spinal cord in females than males [130]. The same group further demonstrated that blockade of coexpressed ERα and GPR30, two types of estrogen receptors (detailed in the following section), substantially decreased MOR/KOR and eliminates mediation by KOR of spinal morphine antinociception, suggesting MOR/KOR could serve as a molecular target for analgesia in women [131] (Figure 1).
Figure 1

Schematic representation of the facilitation of KOR/MOR heterodimerization by E2. Biochemical and behavioral experiments suggest that ERs work cooperatively to increase KOR/MOR expression. We postulate that E2 triggers a signaling complex containing one or multiple ERs, which via an unknown mechanism enhances the formation of KOR/MOR heterodimers and thereby creates the sex difference in opioid actions. Modified from [131].

17β-estradiol (E2), the major ligand of estrogen receptors during reproductive years, rapidly attenuates the ability of μ-opioids to hyperpolarize guinea pig hypothalamic (β-endorphin, an opioid peptide) neurons. E2 does not compete for MOR or alter the affinity of MOR, but binds to a specific receptor that activates PKA to rapidly uncouple MOR from its K+ channel [132]. Increased PKA activity maintains cellular tolerance to MOR agonists in the hypothalamic arcuate nucleus (ARC) neurosecretory cells caused by chronic morphine treatment. Moreover, acute E2 and chronic opioid treatment attenuate MOR-mediated responses via a common PKA pathway [133]. Based on the high density of MOR, but the lack of effects of estrogen on [35S]GTPγS binding, it is concluded that MOR interaction with its G-protein is not the target of estrogen’s actions [134]. E2 may modulate the behavioral effects of cocaine by regulating MOR and KOR signaling in mesocorticolimbic brain structures in female rats [135]. In addition, sex-dependent differences have been found in the intake of ethanol in the absence of β-endorphins in mice [136], and in the regulation of gonadal hormone, DOR binding, and MOR density in the hippocampus by prenatal exposure to morphine in rats [137, 138].

Multiple antinociceptive assays demonstrated that male rats are markedly more sensitive to morphine analgesia than females [128]. The difference cannot be attributed to gender-linked differences in serum levels of morphine after its injection [81], the acute effects of steroids [81], the pharmacokinetics of morphine [83], MOR number and the binding affinity of the MOR agonists [139], and morphine stimulation of G protein determined using GTPase and [35S]GTPγS binding assays [139]. It is postulated that the organizational effects of steroids during critical periods in development, which determine gender-related distinctions, may be significant in the male–female differences [81]. Another explanation for this gender difference is that pathways downstream of MOR and G protein are more efficient in male rats than in female rats such that there is a larger receptor reserve for morphine-mediated antinociception [139]. One mystery that remains poorly understood is that many aspects of sexually dimorphic opioid responsiveness in humans are opposite to that observed in laboratory animals [128].

Opioid regulation of estrogen receptors

Estrogens act on two types of receptors, nuclear estrogen receptors (ERα and ERβ) and the membrane-associated estrogen G protein-coupled receptor (GPR30, also known as GPER). ERα and ERβ modulate the long-lasting effect of estrogen by regulating gene transcription, whereas GPR30 produces more rapid effects by generation of the secondary messengers and activation of receptor tyrosine kinases [140].

Estrogen promotes the growth and development of breast cancer via ER. ERα is the major ER in neoplastic breast epithelium, whereas ERβ is the predominant ER in normal breast tissue [141, 142]. The MOR agonist morphine promotes tumor neovascularization in E2-dependent human breast tumor xenograft model, MCF-7 cell, in mice leading to increased tumor progression at medically relevant concentrations [143]. In contrast, the opioid receptor antagonist naloxone inhibits MCF-7 breast cancer growth in mice [144, 145]. Naloxone modulates ERα activity directly as well as indirectly via MOR, suggesting that naloxone-like compounds can be developed as novel therapeutic molecules for breast cancer therapy [145]. Additionally, ERβ is expressed in human vascular endothelial cells, and morphine down-regulates this receptor as determined by real-time RT-PCR [146]. The DOR agonist SNC80 decrease anxiety- and depression-like behavior following withdrawal from chronic cocaine use in male rats [147], and may serve as a potential anxiolytic in females [148]. Further research focusing on the contribution of circulating hormones and DOR agonists on cocaine withdrawal-induced anxiety in females and understanding the sex differences is needed.

The regulatory actions of opioids on estrogen receptors have been described in breast cancer, yet never been linked to the sex differences in opioid analgesia and addiction. Significance of such opioid actions in the sex difference remains elusive, and may be explored both in vitro and in vivo. The in vitro assays can be done by applying the opioids to neuronal cells expressing specific estrogen receptors to characterize the cellular responses of the estrogen receptors. The in vivo assays measuring the extent of opioid analgesia and addiction in estrogen receptor knockout mice, with females of different stages of estrous cycle and males, should be performed. Specific antagonists to the opioid receptors should be applied to characterize the interacting opioid receptors.

Interactions among opioid and estrogen receptors

MOR internalization is correlated with MOR-mediated inhibition of lordosis [149]. MOR antagonists block receptor internalization and facilitate lordosis [149, 150]. ERα, but not ERβ, is required for estrogen-induced MOR internalization, suggesting that ERα can mediate rapid actions of estrogen [151]. The mRNA of the ORL1 receptor, the non-canonical member of the opioid receptor family, is present in majority of ERα and/or ERβ mRNA-containing neurons, and the sex-related differences in the ORL1 gene expression in the trigeminal nucleus caudalis appear to be determined in part by estrogen levels [152].

GPR30, the plasma membrane ER, is expressed in pain-relevant areas of the rat central nervous system, and the expression levels are similar in the male and female [153156]. GPR30 activation leads to hyperalgesia in rats [157, 158] and spinal nociception in mice [159], and is involved in mediating the rapid pronociceptive effects of E2 [155, 157, 160]. The downstream mechanisms involve cytosolic calcium increase [161, 162], ROS accumulation [163], and neuronal membrane depolarization [159]. Stimulation of plasma membrane ERs is coupled to the activation of the same signaling molecules that participate in most membrane initiated signaling cascades as opioid receptors, e.g., protein kinase A, protein kinase B, protein kinase C, phospholipase C, inositol triphosphate, MAPK, ERK, tyrosine kinases, etc. [164180] Due to the overlapping of the secondary messenger pathways, activation of GPR30 by estrogen is postulated to influence the signaling cascades of the opioid receptors, leading to the sex differences in the effects of opioids because of different GPR30 expression patterns between males and females (Figure 2).
Figure 2

Diagram of the postulated cross-talk between estrogen and opioid receptors. Upon binding of the opioids, opioid receptors (OR) activate different intracellular signaling pathways through the G protein (composed of α, β and γ subunits). The activation of phospholipase C (PLC) catalyzes the hydrolysis of membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces calcium release from the endoplasmic reticulum that activates calcium-dependent signaling. DAG activates protein kinase C (PKC). PKC activates adenylate cyclase (AC), which increases cAMP production, and subsequently stimulates protein kinase A (PKA). PKA can phosphorylate various proteins including ion channels (L-type voltage-gated Ca2+ channels [L-VGCC], G protein-coupled inwardly rectifying K+ channels [GIRK], and small conductance Ca2+-dependent K+ channels [SK]) and cAMP-responsive element binding protein (CREB). The activation of the mitogen-activated protein kinase (MAPK) transduction cascades can stimulate multiple targets, including nuclear transcription factors (such as CREB), cytoplasmic enzymes (including tyrosine hydroxylase), cytoskeletal proteins, and ion channels. Estradiol (E2) can activate the membrane-bound estrogen receptor (mER) and modulate the ionic conductance through phosphorylation of ionotropic receptors or uncoupling of OR from their ionic channels or intracellular effectors. E2 can also bind to nuclear ER dimers and thereby bind to the estrogen-responsive element (ERE) on the DNA, resulting in the activation of specific gene transcription. Additionally, rapid effects of E2 mediated by mER can lead to CREB phosphorylation, altering gene transcription through the interaction with the cAMP responsive element (CRE). Modified from [181].

Although opioids and estrogen can activate common signaling pathways, there is no direct evidence that signaling crosstalk among estrogen and opioid receptors contributes to the sex differences in opioid analgesia and addiction. This data gap should be filled by performing assays measuring the extent of opioid analgesia and addiction in opioid receptor knockout mice, with males and females of different stages of estrous cycle. Specific antagonists to the estrogen receptors are required to identify the interacting estrogen receptors in the behavioral assays.

Conclusions

Although numerous reports have addressed gender differences of opioid receptor agonists, very few directly examined the mechanism. It has been proposed that differences in opioid receptor levels, distribution and efficiency of signaling and neural circuitry modulated by opioid receptor activation cause the sexual dimorphism [129]. However, direct evidence of the interactions among estrogen and opioid receptors is lacking. Animals deficient of estrogen receptors ERα, ERβ, or GPR30 lack the estrogen-regulated opioid effects, and hence display distinct analgesic and addictive responses to morphine. Functional interactions between estrogens and opioids should be investigated to provide the insight into gender differences in analgesia and addiction at both cellular and physiological levels. Male sex hormone such as testosterone may also play a role in opioid analgesia and addiction, as anabolic androgenic steroids have been shown to alter opioid receptor expression in SH-SY5Y human neuroblastoma cells [182]. This review focuses on estrogen receptors, but does not exclude the possibility that androgen receptors could cross-talk with opioid receptors and thereby contribute to the sex differences of opioid effects. Organismal factors must be considered when interpreting the data, since just as a male is not a female, a mouse is not a small rat, and a primate is not a human. Developmental stages, drug doses, routes of drug administration, types of assays employed, and genetic backgrounds should be considered and matched in future randomized clinical studies to define the sex differences in opioid analgesia and addiction.

Abbreviations

AC: 

Adenylate cyclase

DOR: 

δ-opioid receptor

E2: 

17β-estradiol

ERα: 

Estrogen receptor α

ERβ: 

Estrogen receptor β

GPR30/GPER: 

Estrogen G protein-coupled receptor

KOR: 

κ-opioid receptor

MAPK: 

Mitogen-activated protein kinases

MOR: 

μ-opioid receptor

NOP: 

Nociceptin/orphanin FQ peptide

ORL1: 

Opioid receptor-like 1 receptor.

Declarations

Acknowledgements

Financial support for the preparation of this manuscript was provided by the National Health Research Institutes (PD-102-PP-16 and NHRI-102A1-PDCO-1312141) and China Medical University Hospital (DMR-101-123 and DMR-102-029).

Authors’ Affiliations

(1)
Center for Drug Abuse and Addiction, China Medical University Hospital
(2)
China Medical University
(3)
Graduate Institute of Clinical Medical Science, China Medical University
(4)
Center for Neuropsychiatric Research, National Health Research Institutes

References

  1. Coluzzi F, Pappagallo M, National Initiative on Pain C: Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005, 71: 425–433.PubMedGoogle Scholar
  2. Ballantyne JC: Opioid analgesia: perspectives on right use and utility. Pain Physician 2007, 10: 479–491.PubMedGoogle Scholar
  3. Whistler JL: Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012, 121: 189–204. 10.1016/j.drugalcdep.2011.10.031PubMed CentralPubMedView ArticleGoogle Scholar
  4. Portenoy RK: Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996, 11: 203–217.PubMedView ArticleGoogle Scholar
  5. Paulson PE, Minoshima S, Morrow TJ, Casey KL: Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans. Pain 1998, 76: 223–229. 10.1016/S0304-3959(98)00048-7PubMed CentralPubMedView ArticleGoogle Scholar
  6. Manson JE: Pain: sex differences and implications for treatment. Metabolism 2010, 59(Suppl 1):S16-S20.PubMedView ArticleGoogle Scholar
  7. Unruh AM: Gender variations in clinical pain experience. Pain 1996, 65: 123–167. 10.1016/0304-3959(95)00214-6PubMedView ArticleGoogle Scholar
  8. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W: Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011, 37: 313–323. 10.3109/00952990.2011.596982PubMed CentralPubMedView ArticleGoogle Scholar
  9. SAMHSA: Results from the 2011 National Survey on Drug Use and Health: Mental Health Findings. Rockville, MD: NSDUH Series H-45, HHS Publication No. (SMA) 12–4725; 2011. USA: Substance Abuse and Mental Health Services AdministrationGoogle Scholar
  10. Lynch WJ, Roth ME, Carroll ME: Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 2002, 164: 121–137. 10.1007/s00213-002-1183-2View ArticleGoogle Scholar
  11. Carroll ME, Lynch WJ, Roth ME, Morgan AD, Cosgrove KP: Sex and estrogen influence drug abuse. Trends Pharmacol Sci 2004, 25: 273–279. 10.1016/j.tips.2004.03.011PubMedView ArticleGoogle Scholar
  12. Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, Whiteside GT, Brandon NJ: Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol 2009, 2: 215–236.PubMedView ArticleGoogle Scholar
  13. Andersson HI, Ejlertsson G, Leden I, Rosenberg C: Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. Clin J Pain 1993, 9: 174–182. 10.1097/00002508-199309000-00004PubMedView ArticleGoogle Scholar
  14. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ: Chronic pain in Australia: a prevalence study. Pain 2001, 89: 127–134. 10.1016/S0304-3959(00)00355-9PubMedView ArticleGoogle Scholar
  15. Buskila D, Abramov G, Biton A, Neumann L: The prevalence of pain complaints in a general population in Israel and its implications for utilization of health services. J Rheumatol 2000, 27: 1521–1525.PubMedGoogle Scholar
  16. Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK: Epidemiology of chronic non-malignant pain in Denmark. Pain 2003, 106: 221–228. 10.1016/S0304-3959(03)00225-2PubMedView ArticleGoogle Scholar
  17. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK: Chronic pain in Canada–prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002, 7: 179–184.PubMedGoogle Scholar
  18. Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, Borges GL, Bromet EJ, Demytteneare K, de Girolamo G, et al.: Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008, 9: 883–891. 10.1016/j.jpain.2008.05.005PubMedView ArticleGoogle Scholar
  19. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd: Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009, 10: 447–485.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Zimmer C, Basler HD, Vedder H, Lautenbacher S: Sex differences in cortisol response to noxious stress. Clin J Pain 2003, 19: 233–239. 10.1097/00002508-200307000-00006PubMedView ArticleGoogle Scholar
  21. Riley JL 3rd, Robinson ME, Wise EA, Myers CD, Fillingim RB: Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain 1998, 74: 181–187. 10.1016/S0304-3959(97)00199-1PubMedView ArticleGoogle Scholar
  22. Garcia E, Godoy-Izquierdo D, Godoy JF, Perez M, Lopez-Chicheri I: Gender differences in pressure pain threshold in a repeated measures assessment. Psychol Health Med 2007, 12: 567–579. 10.1080/13548500701203433PubMedView ArticleGoogle Scholar
  23. Chesterton LS, Barlas P, Foster NE, Baxter GD, Wright CC: Gender differences in pressure pain threshold in healthy humans. Pain 2003, 101: 259–266. 10.1016/S0304-3959(02)00330-5PubMedView ArticleGoogle Scholar
  24. Fillingim RB, Maixner W, Kincaid S, Silva S: Sex differences in temporal summation but not sensory-discriminative processing of thermal pain. Pain 1998, 75: 121–127. 10.1016/S0304-3959(97)00214-5PubMedView ArticleGoogle Scholar
  25. Nishino T, Isono S, Ishikawa T, Shinozuka N: Sex differences in the effect of dyspnea on thermal pain threshold in young healthy subjects. Anesthesiology 2008, 109: 1100–1106. 10.1097/ALN.0b013e31818d8f43PubMedView ArticleGoogle Scholar
  26. Raak R, Wahren LK: Stress coping strategies in thermal pain sensitive and insensitive healthy subjects. Int J Nurs Pract 2001, 7: 162–168. 10.1046/j.1440-172X.2001.00258.xPubMedView ArticleGoogle Scholar
  27. Racine M, Tousignant-Laflamme Y, Kloda LA, Dion D, Dupuis G, Choiniere M: A systematic literature review of 10 years of research on sex/gender and experimental pain perception - part 1: are there really differences between women and men? Pain 2012, 153: 602–618. 10.1016/j.pain.2011.11.025PubMedView ArticleGoogle Scholar
  28. Edwards RR, Haythornthwaite JA, Sullivan MJ, Fillingim RB: Catastrophizing as a mediator of sex differences in pain: differential effects for daily pain versus laboratory-induced pain. Pain 2004, 111: 335–341. 10.1016/j.pain.2004.07.012PubMedView ArticleGoogle Scholar
  29. Miaskowski C, Levine JD: Does opioid analgesia show a gender preference for females? Pain Forum 1999, 8: 34–44. 10.1016/S1082-3174(99)70044-9View ArticleGoogle Scholar
  30. Chia YY, Chow LH, Hung CC, Liu K, Ger LP, Wang PN: Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth 2002, 49: 249–255. 10.1007/BF03020523PubMedView ArticleGoogle Scholar
  31. Dahan A, Kest B, Waxman AR, Sarton E: Sex-specific responses to opiates: animal and human studies. Anesth Analg 2008, 107: 83–95. 10.1213/ane.0b013e31816a66a4PubMedView ArticleGoogle Scholar
  32. Cepeda MS, Carr DB: Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg 2003, 97: 1464–1468.PubMedView ArticleGoogle Scholar
  33. Aubrun F, Salvi N, Coriat P, Riou B: Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology 2005, 103: 156–160. 10.1097/00000542-200507000-00023PubMedView ArticleGoogle Scholar
  34. Colameco S, Becker LA, Simpson M: Sex bias in the assessment of patient complaints. J Fam Pract 1983, 16: 1117–1121.PubMedGoogle Scholar
  35. Bernstein B, Kane R: Physicians’ attitudes toward female patients. Med Care 1981, 19: 600–608. 10.1097/00005650-198106000-00004PubMedView ArticleGoogle Scholar
  36. Calderone KL: The Influence of Gender on the Frequency of Pain and Sedative Medication Administered to Postoperative-Patients. Sex Roles 1990, 23: 713–725. 10.1007/BF00289259View ArticleGoogle Scholar
  37. DuPont RL: Profile of a heroin-addiction epidemic. N Engl J Med 1971, 285: 320–324. 10.1056/NEJM197108052850605PubMedView ArticleGoogle Scholar
  38. Wu LT, Howard MO: Is inhalant use a risk factor for heroin and injection drug use among adolescents in the United States? Addict Behav 2007, 32: 265–281. 10.1016/j.addbeh.2006.03.043PubMed CentralPubMedView ArticleGoogle Scholar
  39. Maremmani I, Stefania C, Pacini M, Maremmani AG, Carlini M, Golia F, Deltito J, Dell’Osso L: Differential substance abuse patterns distribute according to gender in heroin addicts. J Psychoactive Drugs 2010, 42: 89–95. 10.1080/02791072.2010.10399789PubMedView ArticleGoogle Scholar
  40. Kelly SM, Schwartz RP, O’Grady KE, Mitchell SG, Reisinger HS, Peterson JA, Agar MH, Brown BS: Gender Differences Among In- and Out-of-Treatment Opioid-Addicted Individuals. Am J Drug Alcohol Abuse 2009, 35: 38–42. 10.1080/00952990802342915PubMed CentralPubMedView ArticleGoogle Scholar
  41. De Wilde J, Soyez V, Broekaert E, Rosseel Y, Kaplan C, Larsson J: Problem severity profiles of substance abusing women in European Therapeutic Communities: influence of psychiatric problems. J Subst Abuse Treat 2004, 26: 243–251. 10.1016/j.jsat.2004.01.006PubMedView ArticleGoogle Scholar
  42. Zimmermann G, Pin MA, Krenz S, Bouchat A, Favrat B, Besson J, Zullino DF: Prevalence of social phobia in a clinical sample of drug dependent patients. J Affect Disord 2004, 83: 83–87. 10.1016/j.jad.2004.05.003PubMedView ArticleGoogle Scholar
  43. Kecskes I, Rihmer Z, Kiss K, Sarai T, Szabo A, Kiss GH: Gender differences in panic disorder symptoms and illicit drug use among young people in Hungary. Eur Psychiatry 2002, 17: 29–32.PubMedView ArticleGoogle Scholar
  44. Grilo CM, Martino S, Walker ML, Becker DF, Edell WS, McGlashan TH: Psychiatric comorbidity differences in male and female adult psychiatric inpatients with substance use disorders. Compr Psychiatry 1997, 38: 155–159. 10.1016/S0010-440X(97)90068-7PubMedView ArticleGoogle Scholar
  45. Landheim AS, Bakken K, Vaglum P: Gender differences in the prevalence of symptom disorders and personality disorders among poly-substance abusers and pure alcoholics. Substance abusers treated in two counties in Norway. Eur Addict Res 2003, 9: 8–17. 10.1159/000067732PubMedView ArticleGoogle Scholar
  46. Anker JJ, Carroll ME: Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci 2011, 8: 73–96.PubMedView ArticleGoogle Scholar
  47. McQuay HJ, Bullingham RE, Paterson GM, Moore RA: Clinical effects of buprenorphine during and after operation. Br J Anaesth 1980, 52: 1013–1019. 10.1093/bja/52.10.1013PubMedView ArticleGoogle Scholar
  48. Watson PJ, McQuay HJ, Bullingham RE, Allen MC, Moore RA: Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: clinical effects and plasma concentration. Br J Anaesth 1982, 54: 37–43. 10.1093/bja/54.1.37PubMedView ArticleGoogle Scholar
  49. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA: Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981, 12: 117–122.PubMed CentralPubMedView ArticleGoogle Scholar
  50. Miller PL, Ernst AA: Sex differences in analgesia: a randomized trial of mu versus kappa opioid agonists. South Med J 2004, 97: 35–41. 10.1097/01.SMJ.0000085743.68121.A9PubMedView ArticleGoogle Scholar
  51. Sibille KT, Kindler LL, Glover TL, Gonzalez RD, Staud R, Riley JL 3rd, Fillingim RB: Individual differences in morphine and butorphanol analgesia: a laboratory pain study. Pain Med 2011, 12: 1076–1085. 10.1111/j.1526-4637.2011.01157.xPubMed CentralPubMedView ArticleGoogle Scholar
  52. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 1996, 2: 1248–1250. 10.1038/nm1196-1248PubMedView ArticleGoogle Scholar
  53. Zacny JP, Beckman NJ: The effects of a cold-water stimulus on butorphanol effects in males and females. Pharmacol Biochem Behav 2004, 78: 653–659. 10.1016/j.pbb.2004.01.021PubMedView ArticleGoogle Scholar
  54. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ: Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988, 67: 329–337.PubMedView ArticleGoogle Scholar
  55. Chang KY, Dai CY, Ger LP, Fu MJ, Wong KC, Chan KH, Tsou MY: Determinants of patient-controlled epidural analgesia requirements: a prospective analysis of 1753 patients. Clin J Pain 2006, 22: 751–756. 10.1097/01.ajp.0000210924.56654.03PubMedView ArticleGoogle Scholar
  56. Tamsen A, Bondesson U, Dahlstrom B, Hartvig P: Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. Clin Pharmacokinet 1982, 7: 252–265. 10.2165/00003088-198207030-00005PubMedView ArticleGoogle Scholar
  57. Mercadante S, Casuccio A, Agnello A, Barresi L: Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999, 18: 188–192. 10.1016/S0885-3924(99)00048-2PubMedView ArticleGoogle Scholar
  58. Bennett R, Batenhorst R, Graves DA, Foster TS, Griffen WO, Wright BD: Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy 1982, 2: 50–53.PubMedView ArticleGoogle Scholar
  59. Dahlstrom B, Tamsen A, Paalzow L, Hartvig P: Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982, 7: 266–279. 10.2165/00003088-198207030-00006PubMedView ArticleGoogle Scholar
  60. Bahar M, Rosen M, Vickers MD: Self-administered nalbuphine, morphine and pethidine. Comparison, by intravenous route, following cholecystectomy. Anaesthesia 1985, 40: 529–532.PubMedView ArticleGoogle Scholar
  61. Burns JW, Hodsman NB, McLintock TT, Gillies GW, Kenny GN, McArdle CS: The influence of patient characteristics on the requirements for postoperative analgesia. A reassessment using patient-controlled analgesia. Anaesthesia 1989, 44: 2–6. 10.1111/j.1365-2044.1989.tb11086.xPubMedView ArticleGoogle Scholar
  62. De Kock M, Scholtes JL: Postoperative P.C.A. in abdominal surgery. Analysis of 200 consecutive patients. Acta Anaesthesiol Belg 1991, 42: 85–91.PubMedGoogle Scholar
  63. Tsui SL, Tong WN, Irwin M, Ng KF, Lo JR, Chan WS, Yang J: The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients. Anaesth Intensive Care 1996, 24: 658–664.PubMedGoogle Scholar
  64. Sidebotham D, Dijkhuizen MR, Schug SA: The safety and utilization of patient-controlled analgesia. J Pain Symptom Manage 1997, 14: 202–209. 10.1016/S0885-3924(97)00182-6PubMedView ArticleGoogle Scholar
  65. Lehmann KA, Tenbuhs B: Patient-controlled analgesia with nalbuphine, a new narcotic agonist–antagonist, for the treatment of postoperative pain. Eur J Clin Pharmacol 1986, 31: 267–276. 10.1007/BF00981122PubMedView ArticleGoogle Scholar
  66. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999, 83: 339–345. 10.1016/S0304-3959(99)00119-0PubMedView ArticleGoogle Scholar
  67. Fillingim RB, Hastie BA, Ness TJ, Glover TL, Campbell CM, Staud R: Sex-related psychological predictors of baseline pain perception and analgesic responses to pentazocine. Biol Psychol 2005, 69: 97–112. 10.1016/j.biopsycho.2004.11.008PubMedView ArticleGoogle Scholar
  68. Fillingim RB, Ness TJ, Glover TL, Campbell CM, Price DD, Staud R: Experimental pain models reveal no sex differences in pentazocine analgesia in humans. Anesthesiology 2004, 100: 1263–1270. 10.1097/00000542-200405000-00031PubMedView ArticleGoogle Scholar
  69. Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, Lariviere WR, Groce MK, Wallace MR, Kaplan L, Staud R, et al.: The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A 2003, 100: 4867–4872. 10.1073/pnas.0730053100PubMed CentralPubMedView ArticleGoogle Scholar
  70. Gear RW, Gordon NC, Heller PH, Paul S, Miaskowski C, Levine JD: Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci Lett 1996, 205: 207–209. 10.1016/0304-3940(96)12402-2PubMedView ArticleGoogle Scholar
  71. Tamsen A, Hartvig P, Fagerlund C, Dahlstrom B: Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. Clin Pharmacokinet 1982, 7: 149–163. 10.2165/00003088-198207020-00004PubMedView ArticleGoogle Scholar
  72. Bartok RE, Craft RM: Sex differences in opioid antinociception. J Pharmacol Exp Ther 1997, 282: 769–778.PubMedGoogle Scholar
  73. Terner JM, Barrett AC, Grossell E, Picker MJ: Influence of gonadectomy on the antinociceptive effects of opioids in male and female rats. Psychopharmacology (Berl) 2002, 163: 183–193. 10.1007/s00213-002-1143-xView ArticleGoogle Scholar
  74. Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ: Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl) 2000, 150: 430–442. 10.1007/s002130000453View ArticleGoogle Scholar
  75. Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ: Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl) 2001, 158: 154–164. 10.1007/s002130100821View ArticleGoogle Scholar
  76. Holtman JR Jr, Sloan JW, Jing X, Wala EP: Modification of morphine analgesia and tolerance by flumazenil in male and female rats. Eur J Pharmacol 2003, 470: 149–156. 10.1016/S0014-2999(03)01782-5PubMedView ArticleGoogle Scholar
  77. Lomas LM, Barrett AC, Terner JM, Lysle DT, Picker MJ: Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats. Psychopharmacology (Berl) 2007, 191: 273–285. 10.1007/s00213-006-0663-1View ArticleGoogle Scholar
  78. Thornton SR, Smith FL: Characterization of neonatal rat fentanyl tolerance and dependence. J Pharmacol Exp Ther 1997, 281: 514–521.PubMedGoogle Scholar
  79. Rodriguez M, Carlos MA, Ortega I, Suarez E, Calvo R, Lukas JC: Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. Pharm Res 2002, 19: 858–867. 10.1023/A:1016117218760PubMedView ArticleGoogle Scholar
  80. Baamonde AI, Hidalgo A, Andres-Trelles F: Sex-related differences in the effects of morphine and stress on visceral pain. Neuropharmacology 1989, 28: 967–970. 10.1016/0028-3908(89)90197-4PubMedView ArticleGoogle Scholar
  81. Cicero TJ, Nock B, Meyer ER: Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther 1996, 279: 767–773.PubMedGoogle Scholar
  82. Cicero TJ, Nock B, O’Connor L, Meyer ER: Role of steroids in sex differences in morphine-induced analgesia: activational and organizational effects. J Pharmacol Exp Ther 2002, 300: 695–701. 10.1124/jpet.300.2.695PubMedView ArticleGoogle Scholar
  83. Cicero TJ, Nock B, Meyer ER: Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations. J Pharmacol Exp Ther 1997, 282: 939–944.PubMedGoogle Scholar
  84. Badillo-Martinez D, Kirchgessner AL, Butler PD, Bodnar RJ: Monosodium glutamate and analgesia induced by morphine. Test-specific effects. Neuropharmacology 1984, 23: 1141–1149. 10.1016/0028-3908(84)90231-4PubMedView ArticleGoogle Scholar
  85. Craft RM, Stratmann JA, Bartok RE, Walpole TI, King SJ: Sex differences in development of morphine tolerance and dependence in the rat. Psychopharmacology (Berl) 1999, 143: 1–7. 10.1007/s002130050911View ArticleGoogle Scholar
  86. Craft RM, Lee DA: NMDA antagonist modulation of morphine antinociception in female vs. male rats. Pharmacol Biochem Behav 2005, 80: 639–649. 10.1016/j.pbb.2005.02.003PubMedView ArticleGoogle Scholar
  87. South SM, Wright AW, Lau M, Mather LE, Smith MT: Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance. J Pharmacol Exp Ther 2001, 297: 446–457.PubMedGoogle Scholar
  88. Kepler KL, Kest B, Kiefel JM, Cooper ML, Bodnar RJ: Roles of gender, gonadectomy and estrous phase in the analgesic effects of intracerebroventricular morphine in rats. Pharmacol Biochem Behav 1989, 34: 119–127. 10.1016/0091-3057(89)90363-8PubMedView ArticleGoogle Scholar
  89. Krzanowska EK, Bodnar RJ: Morphine antinociception elicited from the ventrolateral periaqueductal gray is sensitive to sex and gonadectomy differences in rats. Brain Res 1999, 821: 224–230. 10.1016/S0006-8993(98)01364-XPubMedView ArticleGoogle Scholar
  90. Islam AK, Cooper ML, Bodnar RJ: Interactions among aging, gender, and gonadectomy effects upon morphine antinociception in rats. Physiol Behav 1993, 54: 45–53. 10.1016/0031-9384(93)90042-EPubMedView ArticleGoogle Scholar
  91. Kasson BG, George R: Endocrine influences on the actions of morphine: IV. Effects of sex and strain. Life Sci 1984, 34: 1627–1634. 10.1016/0024-3205(84)90633-7PubMedView ArticleGoogle Scholar
  92. Krzanowska EK, Ogawa S, Pfaff DW, Bodnar RJ: Reversal of sex differences in morphine analgesia elicited from the ventrolateral periaqueductal gray in rats by neonatal hormone manipulations. Brain Res 2002, 929: 1–9. 10.1016/S0006-8993(01)03350-9PubMedView ArticleGoogle Scholar
  93. Mousavi Z, Shafaghi B, Kobarfard F, Jorjani M: Sex differences and role of gonadal hormones on glutamate level in the nucleus accumbens in morphine tolerant rats: a microdialysis study. Eur J Pharmacol 2007, 554: 145–149. 10.1016/j.ejphar.2006.10.010PubMedView ArticleGoogle Scholar
  94. Terner JM, Barrett AC, Lomas LM, Negus SS, Picker MJ: Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 2006, 122: 90–101. 10.1016/j.pain.2006.01.019PubMedView ArticleGoogle Scholar
  95. Liu NJ, von Gizycki H, Gintzler AR: Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J Pharmacol Exp Ther 2007, 322: 654–660. 10.1124/jpet.107.123620PubMedView ArticleGoogle Scholar
  96. Lomas LM, Picker MJ: Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists. Psychopharmacology (Berl) 2005, 180: 84–94. 10.1007/s00213-005-2153-2View ArticleGoogle Scholar
  97. Kavaliers M, Innes DG: Developmental changes in opiate-induced analgesia in deer mice: sex and population differences. Brain Res 1990, 516: 326–331. 10.1016/0006-8993(90)90936-6PubMedView ArticleGoogle Scholar
  98. Kavaliers M, Innes D: Sex differences in the effects of neuropeptide FF and IgG from neuropeptide FF on morphine- and stress-induced analgesia. Peptides 1992, 13: 603–607. 10.1016/0196-9781(92)90096-LPubMedView ArticleGoogle Scholar
  99. Kavaliers M, Innes DG: Sex differences in the effects of Tyr-MIF-1 on morphine- and stress-induced analgesia. Peptides 1992, 13: 1295–1297. 10.1016/0196-9781(92)90038-5PubMedView ArticleGoogle Scholar
  100. Candido J, Lutfy K, Billings B, Sierra V, Duttaroy A, Inturrisi CE, Yoburn BC: Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation. Pharmacol Biochem Behav 1992, 42: 685–692. 10.1016/0091-3057(92)90015-8PubMedView ArticleGoogle Scholar
  101. Kest B, Wilson SG, Mogil JS: Sex differences in supraspinal morphine analgesia are dependent on genotype. J Pharmacol Exp Ther 1999, 289: 1370–1375.PubMedGoogle Scholar
  102. Grisel JE, Mogil JS, Belknap JK, Grandy DK: Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. Neuroreport 1996, 7: 2125–2129. 10.1097/00001756-199609020-00012PubMedView ArticleGoogle Scholar
  103. Craft RM, Bernal SA: Sex differences in opioid antinociception: kappa and ‘mixed action’ agonists. Drug Alcohol Depend 2001, 63: 215–228. 10.1016/S0376-8716(00)00209-XPubMedView ArticleGoogle Scholar
  104. Terner JM, Lomas LM, Smith ES, Barrett AC, Picker MJ: Pharmacogenetic analysis of sex differences in opioid antinociception in rats. Pain 2003, 106: 381–391. 10.1016/j.pain.2003.08.008PubMedView ArticleGoogle Scholar
  105. Lynch WJ, Carroll ME: Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. Psychopharmacology (Berl) 1999, 144: 77–82. 10.1007/s002130050979View ArticleGoogle Scholar
  106. Carroll ME, Morgan AD, Lynch WJ, Campbell UC, Dess NK: Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences. Psychopharmacology (Berl) 2002, 161: 304–313. 10.1007/s00213-002-1030-5View ArticleGoogle Scholar
  107. Cicero TJ, Aylward SC, Meyer ER: Gender differences in the intravenous self-administration of mu opiate agonists. Pharmacol Biochem Behav 2003, 74: 541–549. 10.1016/S0091-3057(02)01039-0PubMedView ArticleGoogle Scholar
  108. Wetherington CL: Sex differences and gonadal hormone influences in drug addiction and sexual behavior: progress and possibilities. Horm Behav 2010, 58: 2–7. 10.1016/j.yhbeh.2010.03.004PubMedView ArticleGoogle Scholar
  109. Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ: Gender effects and central opioid analgesia. Pain 1991, 45: 87–94. 10.1016/0304-3959(91)90168-WPubMedView ArticleGoogle Scholar
  110. Ali BH, Sharif SI, Elkadi A: Sex differences and the effect of gonadectomy on morphine-induced antinociception and dependence in rats and mice. Clin Exp Pharmacol Physiol 1995, 22: 342–344. 10.1111/j.1440-1681.1995.tb02012.xPubMedView ArticleGoogle Scholar
  111. Ratka A, Simpkins JW: Effects of estradiol and progesterone on the sensitivity to pain and on morphine-induced antinociception in female rats. Horm Behav 1991, 25: 217–228. 10.1016/0018-506X(91)90052-JPubMedView ArticleGoogle Scholar
  112. Chatterjee TK, Das S, Banerjee P, Ghosh JJ: Possible physiological role of adrenal and gonadal steroids in morphine analgesia. Eur J Pharmacol 1982, 77: 119–123. 10.1016/0014-2999(82)90005-XPubMedView ArticleGoogle Scholar
  113. Kasson BG, George R: Endocrine influences on the actions of morphine. I. Alteration of target gland hormones. J Pharmacol Exp Ther 1983, 224: 273–281.PubMedGoogle Scholar
  114. Banerjee P, Chatterjee TK, Ghosh JJ: Ovarian steroids and modulation of morphine-induced analgesia and catalepsy in female rats. Eur J Pharmacol 1983, 96: 291–294. 10.1016/0014-2999(83)90319-9PubMedView ArticleGoogle Scholar
  115. Borzan J, Fuchs PN: Organizational and activational effects of testosterone on carrageenan-induced inflammatory pain and morphine analgesia. Neuroscience 2006, 143: 885–893. 10.1016/j.neuroscience.2006.08.034PubMedView ArticleGoogle Scholar
  116. Stoffel EC, Ulibarri CM, Craft RM: Gonadal steroid hormone modulation of nociception, morphine antinociception and reproductive indices in male and female rats. Pain 2003, 103: 285–302. 10.1016/s0304-3959(02)00457-8PubMed CentralPubMedView ArticleGoogle Scholar
  117. Dawson-Basoa ME, Gintzler AR: Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain 1996, 64: 608–615. 10.1016/0304-3959(96)87175-2PubMedView ArticleGoogle Scholar
  118. Claiborne J, Nag S, Mokha SS: Activation of opioid receptor like-1 receptor in the spinal cord produces sex-specific antinociception in the rat: estrogen attenuates antinociception in the female, whereas testosterone is required for the expression of antinociception in the male. J Neurosci 2006, 26: 13048–13053. 10.1523/JNEUROSCI.4783-06.2006PubMedView ArticleGoogle Scholar
  119. Kieffer BL, Evans CJ: Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 2009, 56(Suppl 1):205–212.PubMed CentralPubMedView ArticleGoogle Scholar
  120. Zaveri NT: The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem 2011, 11: 1151–1156. 10.2174/156802611795371341PubMed CentralPubMedView ArticleGoogle Scholar
  121. Pierre S, Eschenhagen T, Geisslinger G, Scholich K: Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 2009, 8: 321–335. 10.1038/nrd2827PubMedView ArticleGoogle Scholar
  122. Christie MJ: Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008, 154: 384–396.PubMed CentralPubMedView ArticleGoogle Scholar
  123. Law PY, Wong YH, Loh HH: Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000, 40: 389–430. 10.1146/annurev.pharmtox.40.1.389PubMedView ArticleGoogle Scholar
  124. McEwen BS: Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001, 91: 2785–2801.PubMedGoogle Scholar
  125. Genazzani AR, Petraglia F, Volpe A, Facchinetti F: Estrogen changes as a critical factor in modulation of central opioid tonus: possible correlations with post-menopausal migraine. Cephalalgia 1985, 5(Suppl 2):212–214.PubMedGoogle Scholar
  126. Gravanis A, Makrigiannakis A, Stournaras C, Margioris AN: Interaction between steroid hormones and endometrial opioids. Ann N Y Acad Sci 1994, 734: 245–256. 10.1111/j.1749-6632.1994.tb21754.xPubMedView ArticleGoogle Scholar
  127. Dawson-Basoa M, Gintzler AR: Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 1997, 757: 37–42. 10.1016/S0006-8993(97)00092-9PubMedView ArticleGoogle Scholar
  128. Gintzler AR, Liu NJ: Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors. Front Neuroendocrinol 2012, 33: 412–424. 10.1016/j.yfrne.2012.09.004PubMed CentralPubMedView ArticleGoogle Scholar
  129. Rasakham K, Liu-Chen LY: Sex differences in kappa opioid pharmacology. Life Sci 2011, 88: 2–16. 10.1016/j.lfs.2010.10.007PubMedView ArticleGoogle Scholar
  130. Chakrabarti S, Liu NJ, Gintzler AR: Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A 2010, 107: 20115–20119. 10.1073/pnas.1009923107PubMed CentralPubMedView ArticleGoogle Scholar
  131. Liu NJ, Chakrabarti S, Schnell S, Wessendorf M, Gintzler AR: Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal kappa- and mu-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 2011, 31: 11836–11845. 10.1523/JNEUROSCI.1901-11.2011PubMed CentralPubMedView ArticleGoogle Scholar
  132. Lagrange AH, Ronnekleiv OK, Kelly MJ: Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A. Mol Pharmacol 1997, 51: 605–612.PubMedGoogle Scholar
  133. Wagner EJ, Ronnekleiv OK, Kelly MJ: Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling. J Pharmacol Exp Ther 1998, 285: 1266–1273.PubMedGoogle Scholar
  134. Cunningham MJ, Fang Y, Selley DE, Kelly MJ: mu-Opioid agonist-stimulated [35S]GTPgammaS binding in guinea pig hypothalamus: effects of estrogen. Brain Res 1998, 791: 341–346. 10.1016/S0006-8993(98)00201-7PubMedView ArticleGoogle Scholar
  135. Segarra AC, Agosto-Rivera JL, Febo M, Lugo-Escobar N, Menendez-Delmestre R, Puig-Ramos A, Torres-Diaz YM: Estradiol: a key biological substrate mediating the response to cocaine in female rats. Horm Behav 2010, 58: 33–43. 10.1016/j.yhbeh.2009.12.003PubMed CentralPubMedView ArticleGoogle Scholar
  136. Racz I, Schurmann B, Karpushova A, Reuter M, Cichon S, Montag C, Furst R, Schutz C, Franke PE, Strohmaier J, et al.: The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol Psychiatry 2008, 64: 989–997. 10.1016/j.biopsych.2008.05.008PubMed CentralPubMedView ArticleGoogle Scholar
  137. Vathy I, Rimanoczy A, Slamberova R: Prenatal exposure to morphine differentially alters gonadal hormone regulation of delta-opioid receptor binding in male and female rats. Brain Res Bull 2000, 53: 793–800. 10.1016/S0361-9230(00)00409-3PubMedView ArticleGoogle Scholar
  138. Slamberova R, Rimanoczy A, Bar N, Schindler CJ, Vathy I: Density of mu-opioid receptors in the hippocampus of adult male and female rats is altered by prenatal morphine exposure and gonadal hormone treatment. Hippocampus 2003, 13: 461–471. 10.1002/hipo.10076PubMedView ArticleGoogle Scholar
  139. Peckham EM, Barkley LM, Divin MF, Cicero TJ, Traynor JR: Comparison of the antinociceptive effect of acute morphine in female and male Sprague–Dawley rats using the long-lasting mu-antagonist methocinnamox. Brain Res 2005, 1058: 137–147. 10.1016/j.brainres.2005.07.060PubMedView ArticleGoogle Scholar
  140. Prossnitz ER, Arterburn JB, Sklar LA: GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 2007, 265–266: 138–142.PubMed CentralPubMedView ArticleGoogle Scholar
  141. Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001, 276: 36869–36872. 10.1074/jbc.R100029200PubMedView ArticleGoogle Scholar
  142. Khan SA, Rogers MA, Obando JA, Tamsen A: Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994, 54: 993–997.PubMedGoogle Scholar
  143. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002, 62: 4491–4498.PubMedGoogle Scholar
  144. Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, Niederberger E, Scholich K, Geisslinger G: G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 2003, 63: 1846–1852.PubMedGoogle Scholar
  145. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K: Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006, 5: 611–620. 10.1158/1535-7163.MCT-05-0016PubMedView ArticleGoogle Scholar
  146. Cadet P, Mantione K, Bilfinger TV, Stefano GB: Morphine down regulates human vascular tissue estrogen receptor expression determined by real-time RT-PCR. Neuro Endocrinol Lett 2002, 23: 95–100.PubMedGoogle Scholar
  147. Perrine SA, Sheikh IS, Nwaneshiudu CA, Schroeder JA, Unterwald EM: Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology 2008, 54: 355–364. 10.1016/j.neuropharm.2007.10.007PubMed CentralPubMedView ArticleGoogle Scholar
  148. Ambrose-Lanci LM, Sterling RC, Van Bockstaele EJ: Cocaine withdrawal-induced anxiety in females: impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment. J Neurosci Res 2010, 88: 816–824.PubMed CentralPubMedGoogle Scholar
  149. Sinchak K, Micevych PE: Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. J Neurosci 2001, 21: 5723–5729.PubMedGoogle Scholar
  150. Eckersell CB, Popper P, Micevych PE: Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci 1998, 18: 3967–3976.PubMedGoogle Scholar
  151. Micevych PE, Rissman EF, Gustafsson JA, Sinchak K: Estrogen receptor-alpha is required for estrogen-induced mu-opioid receptor internalization. J Neurosci Res 2003, 71: 802–810. 10.1002/jnr.10526PubMedView ArticleGoogle Scholar
  152. Flores CA, Shughrue P, Petersen SL, Mokha SS: Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 2003, 118: 769–778. 10.1016/S0306-4522(02)01000-XPubMedView ArticleGoogle Scholar
  153. Dun SL, Brailoiu GC, Gao X, Brailoiu E, Arterburn JB, Prossnitz ER, Oprea TI, Dun NJ: Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. J Neurosci Res 2009, 87: 1610–1619. 10.1002/jnr.21980PubMed CentralPubMedView ArticleGoogle Scholar
  154. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O’Carroll AM, Lolait SJ: Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol 2009, 202: 223–236. 10.1677/JOE-09-0066PubMed CentralPubMedView ArticleGoogle Scholar
  155. Liverman CS, Brown JW, Sandhir R, McCarson KE, Berman NE: Role of the oestrogen receptors GPR30 and ERalpha in peripheral sensitization: relevance to trigeminal pain disorders in women. Cephalalgia 2009, 29: 729–741. 10.1111/j.1468-2982.2008.01789.xPubMed CentralPubMedView ArticleGoogle Scholar
  156. Takanami K, Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Prossnitz ER, Kawata M: Expression of G protein-coupled receptor 30 in the spinal somatosensory system. Brain Res 2010, 1310: 17–28.PubMedView ArticleGoogle Scholar
  157. Kuhn J, Dina OA, Goswami C, Suckow V, Levine JD, Hucho T: GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. Eur J Neurosci 2008, 27: 1700–1709. 10.1111/j.1460-9568.2008.06131.xPubMedView ArticleGoogle Scholar
  158. Lu CL, Hsieh JC, Dun NJ, Oprea TI, Wang PS, Luo JC, Lin HC, Chang FY, Lee SD: Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 2009, 137: 1040–1050. 10.1053/j.gastro.2009.03.047PubMedView ArticleGoogle Scholar
  159. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ, Brailoiu E: Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. J Pain 2012, 13: 742–754. 10.1016/j.jpain.2012.05.011PubMed CentralPubMedView ArticleGoogle Scholar
  160. Fehrenbacher JC, Loverme J, Clarke W, Hargreaves KM, Piomelli D, Taylor BK: Rapid pain modulation with nuclear receptor ligands. Brain Res Rev 2009, 60: 114–124. 10.1016/j.brainresrev.2008.12.019PubMed CentralPubMedView ArticleGoogle Scholar
  161. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, et al.: The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 2010, 70: 1184–1194. 10.1158/0008-5472.CAN-09-3068PubMed CentralPubMedView ArticleGoogle Scholar
  162. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307: 1625–1630. 10.1126/science.1106943PubMedView ArticleGoogle Scholar
  163. Kim HY, Lee KY, Lu Y, Wang J, Cui L, Kim SJ, Chung JM, Chung K: Mitochondrial Ca(2+) uptake is essential for synaptic plasticity in pain. J Neurosci 2011, 31: 12982–12991. 10.1523/JNEUROSCI.3093-11.2011PubMed CentralPubMedView ArticleGoogle Scholar
  164. Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994, 91: 8517–8521. 10.1073/pnas.91.18.8517PubMed CentralPubMedView ArticleGoogle Scholar
  165. Bi R, Broutman G, Foy MR, Thompson RF, Baudry M: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci U S A 2000, 97: 3602–3607. 10.1073/pnas.97.7.3602PubMed CentralPubMedView ArticleGoogle Scholar
  166. Cardona-Gomez GP, Mendez P, Garcia-Segura LM: Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of PI3K/Akt signaling in the adult rat hypothalamus. Brain Res Mol Brain Res 2002, 107: 80–88. 10.1016/S0169-328X(02)00449-7PubMedView ArticleGoogle Scholar
  167. Gu Q, Moss RL: 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci 1996, 16: 3620–3629.PubMedGoogle Scholar
  168. Lieberherr M, Grosse B, Kachkache M, Balsan S: Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors. J Bone Miner Res 1993, 8: 1365–1376.PubMedView ArticleGoogle Scholar
  169. Marino M, Pallottini V, Trentalance A: Estrogens cause rapid activation of IP3-PKC-alpha signal transduction pathway in HEPG2 cells. Biochem Biophys Res Commun 1998, 245: 254–258. 10.1006/bbrc.1998.8413PubMedView ArticleGoogle Scholar
  170. Mendoza C, Soler A, Tesarik J: Nongenomic steroid action: independent targeting of a plasma membrane calcium channel and a tyrosine kinase. Biochem Biophys Res Commun 1995, 210: 518–523. 10.1006/bbrc.1995.1690PubMedView ArticleGoogle Scholar
  171. Minami T, Oomura Y, Nabekura J, Fukuda A: 17 beta-estradiol depolarization of hypothalamic neurons is mediated by cyclic AMP. Brain Res 1990, 519: 301–307. 10.1016/0006-8993(90)90092-PPubMedView ArticleGoogle Scholar
  172. Mobbs CV, Kaplitt M, Kow LM, Pfaff DW: PLC-alpha: a common mediator of the action of estrogen and other hormones? Mol Cell Endocrinol 1991, 80: C187-C191. 10.1016/0303-7207(91)90136-GPubMedView ArticleGoogle Scholar
  173. Nabekura J, Oomura Y, Minami T, Mizuno Y, Fukuda A: Mechanism of the rapid effect of 17 beta-estradiol on medial amygdala neurons. Science 1986, 233: 226–228. 10.1126/science.3726531PubMedView ArticleGoogle Scholar
  174. Qiu J, Bosch MA, Tobias SC, Grandy DK, Scanlan TS, Ronnekleiv OK, Kelly MJ: Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci 2003, 23: 9529–9540.PubMedGoogle Scholar
  175. Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 1999, 13: 307–319. 10.1210/me.13.2.307PubMedGoogle Scholar
  176. Singh M, Setalo G Jr, Guan X, Warren M, Toran-Allerand CD: Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 1999, 19: 1179–1188.PubMedGoogle Scholar
  177. Szego CM, Davis JS: Adenosine 3′,5′-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A 1967, 58: 1711–1718. 10.1073/pnas.58.4.1711PubMed CentralPubMedView ArticleGoogle Scholar
  178. Toran-Allerand CD, Singh M, Setalo G Jr: Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol 1999, 20: 97–121. 10.1006/frne.1999.0177PubMedView ArticleGoogle Scholar
  179. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138: 4030–4033. 10.1210/en.138.9.4030PubMedView ArticleGoogle Scholar
  180. Zhou Y, Watters JJ, Dorsa DM: Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996, 137: 2163–2166. 10.1210/en.137.5.2163PubMedGoogle Scholar
  181. Cornil CA, Ball GF, Balthazart J: Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from? Brain Res 2006, 1126: 2–26. 10.1016/j.brainres.2006.07.098PubMed CentralPubMedView ArticleGoogle Scholar
  182. Guarino G, Spampinato S: Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells. Neuroreport 2008, 19: 1131–1135. 10.1097/WNR.0b013e328305639dPubMedView ArticleGoogle Scholar

Copyright

© Lee and Ho; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement